UBS Group
IRWD icon

UBS Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

UBS Group’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.28M Buy
933,225
+422,682
+83% +$1.73M ﹤0.01% 4502
2025
Q4 		$1.72M Sell
510,543
-301,121
-37% -$782K ﹤0.01% 5103
2025
Q3 		$1.06M Buy
811,664
+511,554
+170% +$529K ﹤0.01% 5525
2025
Q2 		$215K Buy
300,110
+175,839
+141% +$138K ﹤0.01% 6671
2025
Q1 		$183K Sell
124,271
-2,054,990
-94% -$4.89M ﹤0.01% 6615
2024
Q4 		$9.65M Buy
2,179,261
+1,232,377
+130% +$5M ﹤0.01% 3090
2024
Q3 		$3.9M Sell
946,884
-892,915
-49% -$4.8M ﹤0.01% 3333
2024
Q2 		$12M Sell
1,839,799
-1,187,916
-39% -$8.4M ﹤0.01% 2076
2024
Q1 		$26.4M Buy
3,027,715
+2,582,407
+580% +$31.3M 0.01% 1476
2023
Q4 		$5.09M Sell
445,308
-449,766
-50% -$4.45M ﹤0.01% 2767
2023
Q3 		$8.62M Buy
895,074
+207,756
+30% +$2.04M ﹤0.01% 2100
2023
Q2 		$7.31M Sell
687,318
-99,766
-13% -$1.07M ﹤0.01% 2229
2023
Q1 		$8.28M Sell
787,084
-33,197
-4% -$372K ﹤0.01% 2040
2022
Q4 		$10.2M Buy
820,281
+712,596
+662% +$8.08M ﹤0.01% 1918
2022
Q3 		$1.11M Sell
107,685
-9,468
-8% -$107K ﹤0.01% 3662
2022
Q2 		$1.35M Sell
117,153
-313,078
-73% -$3.69M ﹤0.01% 3468
2022
Q1 		$5.41M Sell
430,231
-28,067
-6% -$322K ﹤0.01% 2460
2021
Q4 		$5.34M Sell
458,298
-164,359
-26% -$2.02M ﹤0.01% 2747
2021
Q3 		$8.13M Buy
622,657
+231,156
+59% +$2.99M ﹤0.01% 2210
2021
Q2 		$5.04M Buy
391,501
+383,281
+4,663% +$4.39M ﹤0.01% 2675
2021
Q1 		$92K Buy
8,220
+2,069
+34% +$21.9K ﹤0.01% 6029
2020
Q4 		$70K Sell
6,151
-59,640
-91% -$653K ﹤0.01% 5923
2020
Q3 		$592K Sell
65,791
-64,734
-50% -$643K ﹤0.01% 4052
2020
Q2 		$1.35M Sell
130,525
-322,425
-71% -$3.3M ﹤0.01% 3251
2020
Q1 		$4.57M Sell
452,950
-305,929
-40% -$3.6M ﹤0.01% 2006
2019
Q4 		$10.1M Sell
758,879
-176,735
-19% -$1.95M ﹤0.01% 1941
2019
Q3 		$8.03M Buy
935,614
+513,070
+121% +$4.99M ﹤0.01% 1941
2019
Q2 		$4.62M Sell
422,544
-57,904
-12% -$649K ﹤0.01% 2390
2019
Q1 		$4.55M Sell
480,448
-548,544
-53% -$6.13M ﹤0.01% 2284
2018
Q4 		$8.93M Buy
1,028,992
+168,926
+20% +$1.94M ﹤0.01% 1662
2018
Q3 		$13.3M Buy
860,066
+597,343
+227% +$9.44M 0.01% 1534
2018
Q2 		$4.21M Buy
262,723
+77,704
+42% +$1.15M ﹤0.01% 2495
2018
Q1 		$2.39M Buy
185,019
+159,568
+627% +$1.99M ﹤0.01% 2989
2017
Q4 		$319K Sell
25,451
-35,613
-58% -$465K ﹤0.01% 4599
2017
Q3 		$807K Buy
61,064
+46,134
+309% +$635K ﹤0.01% 3868
2017
Q2 		$236K Buy
14,930
+14,389
+2,660% +$209K ﹤0.01% 4648
2017
Q1 		$8K Sell
541
-64,142
-99% -$877K ﹤0.01% 6746
2016
Q4 		$828K Buy
64,683
+64,517
+38,866% +$815K ﹤0.01% 3710
2016
Q3 		$2K Sell
166
-20,558
-99% -$240K ﹤0.01% 7406
2016
Q2 		$227K Buy
20,724
+10,269
+98% +$100K ﹤0.01% 4470
2016
Q1 		$95K Sell
10,455
-125,489
-92% -$1.04M ﹤0.01% 5027
2015
Q4 		$1.32M Buy
135,944
+132,859
+4,307% +$1.28M ﹤0.01% 3173
2015
Q3 		$27K Buy
3,085
+6
+0.2% +$56 ﹤0.01% 6403
2015
Q2 		$31K Buy
3,079
+333
+12% +$3.87K ﹤0.01% 6446
2015
Q1 		$37K Sell
2,746
-4,192
-60% -$55K ﹤0.01% 6326
2014
Q4 		$89K Buy
+6,938
New +$79.4K ﹤0.01% 5814

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's IRWD Position: Q1 2026 in Review

UBS Group increased its Ironwood Pharmaceuticals (IRWD) stake by 83% in Q1 2026, buying an estimated $1.73M and bringing the position to 933,225 shares worth $3.28M. The position accounts for ﹤0.01% of the portfolio, ranked #4502.

UBS Group first reported a position in IRWD in Q4 2014 and has held it in 46 quarters since. The position peaked at $26.4M in Q1 2024. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • UBS Group held 933,225 shares of Ironwood Pharmaceuticals worth $3.28M as of Q1 2026.
  • UBS Group bought 422,682 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $1.73M.
  • Ironwood Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4502 holding.
  • UBS Group first reported a position in Ironwood Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Ironwood Pharmaceuticals position peaked at $26.4M in Q1 2024.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.